Valent BioSciences announces the acquisition of FBSciences

Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions. With this acquisition, Valent BioSciences and its parent company, Sumitomo Chemical Co., Ltd., now offer an innovative and proven portfolio of integrated biorational solutions, including biostimulants, biopesticides, and crop nutrition solutions.

The acquisition of FBSciences, a recognized leader in biostimulants headquartered in Collierville, Tennessee, greatly strengthens Valent BioSciences’ participation in the rapidly growing $3.5 billion global biostimulant market. On October 1, 2022, Valent BioSciences began selling biostimulant products directly to its U.S. customer base. This acquisition will provide a significant growth platform for the two companies’ wide range of crop enhancement and crop protection products and forms a key pillar in the overall business strategy.

FBSciences’ portfolio of biorational technologies is naturally derived, renewable, and sustainable, and forms the foundation of a wide offering of innovative solutions for agriculture. The company’s core technologies are derived from natural organic matter (NOM) utilizing proprietary production processes that target and extract a diverse mixture of unique and biologically active compounds that transform plant, soil, and climate health. With a science-based approach and decades of research, FBSciences delivers powerful technologies and products with a track record of superior performance and proven commercial success.

The company’s flagship biostimulant technology, FBS Transit®, forms the foundation of its crop nutrition and nutrient use efficiency product lines for use on all crops. It works inside the plant to increase the uptake and translocation of all nutrients, leading to healthier plants that can withstand stress, which results in increased yields and quality.

FBSciences’ biopesticide technology, FBS Defense™, works within the plant to increase its ability to defend itself from biotic stresses, including insects and diseases, and increases harvestable yields.

Both companies are well recognized for their industry-leading research and development capabilities, which will spark rapid innovation and commercialization of new technologies and products to deliver substantial growth for the biorationals arena.

The acquisition of FBSciences is a natural next step in the evolution of our organization as a global leader in biorationals, including biostimulants. Our combined organizations have many decades of experience leading our respective markets with science-based technology and innovation. The wide range of biostimulant, biopesticide, and crop nutrition products and technologies in the FBSciences portfolio augments Valent BioSciences’ broad family of biorational products, thereby creating an unmatched range of value-added and sustainable solutions that no other company can provide.”

Ted Melnik, President and CEO, Valent BioSciences.

Sumitomo Chemical has pledged to achieve carbon neutrality by 2050, aiming to reduce the amount of greenhouse gases emitted by its production and business activities.

Valent BioSciences’ keen focus on developing products that sequester atmospheric carbon, combined with FBSciences’ technologies, will help accelerate this effort. This acquisition will step forward our Green Transformation strategy initiatives and contribute to realizing sustainable agriculture and society in the future.”

Nobuaki Mito, Director and Senior Managing Executive Officer, Sumitomo Chemical.

The acquisition of FBSciences by Valent BioSciences is a major leap forward for the biorational industry. This tremendous milestone for FBSciences recognizes 16 years of success developing and commercializing transformative plant, soil, and climate health solutions. Our companies share a common rooted-in-science approach coupled with a mission to better society and our planet. Adding FBSciences’ expertise, innovative solutions, and entrepreneurial spirit to Valent BioSciences’ global powerhouse of resources and robust solutions will deliver a platform unrivaled in the industry and continue to propel Valent BioSciences’ leadership position in the rapidly growing biorational space.”

Courtenay Wolfe, CEO and Chairwoman, FBSciences. 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Valent Biosciences. (2023, February 13). Valent BioSciences announces the acquisition of FBSciences. AZoLifeSciences. Retrieved on April 15, 2024 from https://www.azolifesciences.com/news/20230213/Valent-BioSciences-announces-the-acquisition-of-FBSciences.aspx.

  • MLA

    Valent Biosciences. "Valent BioSciences announces the acquisition of FBSciences". AZoLifeSciences. 15 April 2024. <https://www.azolifesciences.com/news/20230213/Valent-BioSciences-announces-the-acquisition-of-FBSciences.aspx>.

  • Chicago

    Valent Biosciences. "Valent BioSciences announces the acquisition of FBSciences". AZoLifeSciences. https://www.azolifesciences.com/news/20230213/Valent-BioSciences-announces-the-acquisition-of-FBSciences.aspx. (accessed April 15, 2024).

  • Harvard

    Valent Biosciences. 2023. Valent BioSciences announces the acquisition of FBSciences. AZoLifeSciences, viewed 15 April 2024, https://www.azolifesciences.com/news/20230213/Valent-BioSciences-announces-the-acquisition-of-FBSciences.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.